trending Market Intelligence /marketintelligence/en/news-insights/trending/ytgZR7_gy1VWiiRzzd30jw2 content esgSubNav
In This List

Global Blood Therapeutics prices $100M common stock offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Global Blood Therapeutics prices $100M common stock offering

Global Blood Therapeutics Inc. priced its underwritten public offering of common stock for gross proceeds of about $100 million.

The company granted the underwriters an option to buy up an additional $15 million of common stock.

The offering is expected to close Dec. 19, subject to customary closing conditions.

Global Blood plans to use the net proceeds to fund the clinical development of voxelotor for treating sickle cell disease and other clinical trials. It also intends to use the net proceeds for other research and development activities, working capital, and general corporate purposes.

Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering.